User login
Key clinical point: Minimal important change (MIC) of the Psoriatic Arthritis Disease Activity Score (PASDAS) could help physicians understand patients' perspectives of disease activity and provide an additional tool for the treatment of psoriatic arthritis (PsA).
Major finding: The overall MIC of the PASDAS was 0.67 (95% CI 0.55-0.79) and results for improvement and deterioration were 0.65 (95% CI 0.46-0.83) and 0.71 (95% CI 0.49-0.93), respectively.
Study details: Findings are from a retrospective cohort study that evaluated routine practice data of 408 patients with PsA.
Disclosures: This work was supported by the Regional Junior Researcher Grant from the Sint Maartenskliniek, Nijmegen, and the Radboudumc, Nijmegen, the Netherlands. The authors declared no conflicts of interest.
Source: Mulder MLM et al. Rheumatology (Oxford). 2022 (Jan 13). Doi: 10.1093/rheumatology/keac025.
Key clinical point: Minimal important change (MIC) of the Psoriatic Arthritis Disease Activity Score (PASDAS) could help physicians understand patients' perspectives of disease activity and provide an additional tool for the treatment of psoriatic arthritis (PsA).
Major finding: The overall MIC of the PASDAS was 0.67 (95% CI 0.55-0.79) and results for improvement and deterioration were 0.65 (95% CI 0.46-0.83) and 0.71 (95% CI 0.49-0.93), respectively.
Study details: Findings are from a retrospective cohort study that evaluated routine practice data of 408 patients with PsA.
Disclosures: This work was supported by the Regional Junior Researcher Grant from the Sint Maartenskliniek, Nijmegen, and the Radboudumc, Nijmegen, the Netherlands. The authors declared no conflicts of interest.
Source: Mulder MLM et al. Rheumatology (Oxford). 2022 (Jan 13). Doi: 10.1093/rheumatology/keac025.
Key clinical point: Minimal important change (MIC) of the Psoriatic Arthritis Disease Activity Score (PASDAS) could help physicians understand patients' perspectives of disease activity and provide an additional tool for the treatment of psoriatic arthritis (PsA).
Major finding: The overall MIC of the PASDAS was 0.67 (95% CI 0.55-0.79) and results for improvement and deterioration were 0.65 (95% CI 0.46-0.83) and 0.71 (95% CI 0.49-0.93), respectively.
Study details: Findings are from a retrospective cohort study that evaluated routine practice data of 408 patients with PsA.
Disclosures: This work was supported by the Regional Junior Researcher Grant from the Sint Maartenskliniek, Nijmegen, and the Radboudumc, Nijmegen, the Netherlands. The authors declared no conflicts of interest.
Source: Mulder MLM et al. Rheumatology (Oxford). 2022 (Jan 13). Doi: 10.1093/rheumatology/keac025.